Seo et al. developed a quantitative method using ultra-high-performance liquid chromatography-tandem mass spectrometry to distinguish between HBP metabolites in KRAS wild-type and mutant lung cancer cells, providing a valuable tool for metabolic research in cancer and the development of new anticancer drugs [48]. Here, KRAS is linked to lung carcinoma.